Globus Medical (NYSE:GMED) Shares Bought by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Globus Medical, Inc. (NYSE:GMED). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Globus Medical stock on September 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Globus Medical Price Performance

Globus Medical stock opened at $76.30 on Thursday. The stock has a market cap of $10.24 billion, a price-to-earnings ratio of 19.51, a price-to-earnings-growth ratio of 1.23 and a beta of 0.96. The firm has a 50-day moving average of $78.82 and a two-hundred day moving average of $81.52. Globus Medical, Inc. has a 1 year low of $57.67 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same quarter last year, the firm posted $0.86 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on GMED shares. Wells Fargo & Company lowered their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. BMO Capital Markets assumed coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective on the stock. Royal Bank Of Canada reduced their target price on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Stifel Nicolaus decreased their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday, July 8th. Finally, UBS Group began coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and an average price target of $99.46.

Insider Activity

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 18.38% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. Janus Henderson Group PLC lifted its stake in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Sculptor Capital LP increased its position in shares of Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares during the last quarter. Madison Avenue Partners LP increased its position in shares of Globus Medical by 3.0% during the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock worth $229,167,000 after purchasing an additional 76,588 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Globus Medical by 2.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock valued at $97,557,000 after buying an additional 30,412 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Globus Medical Company Profile

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.